| Literature DB >> 26807265 |
Byeong-Jin Ye1, Byoung-Gwon Kim2, Man-Joong Jeon3, Se-Yeong Kim4, Hawn-Cheol Kim5, Tae-Won Jang6, Hong-Jae Chae7, Won-Jun Choi8, Mi-Na Ha9, Young-Seoub Hong2.
Abstract
Mercury occurs in various chemical forms, and it is different to health effects according to chemical forms. In consideration of the point, the evaluation of the mercury exposure to human distinguished from occupational and environmental exposure. With strict to manage occupational exposure in factory, it is declined mercury intoxication cases by metallic and inorganic mercury inhalation to occupational exposure. It is increasing to importance in environmental exposure and public health. The focus on the health impact of exposure to mercury is more on chronic, low or moderate grade exposure-albeit a topic of great controversy-, not high concentration exposure by methylmercury, which caused Minamata disease. Recently, the issue of mercury toxicity according to the mercury exposure level, health effects as well as the determination of what mercury levels affect health are in the spotlight and under active discussion. Evaluating the health effects and Biomarker of mercury exposure and establishing diagnosis and treatment standards are very difficult. It can implement that evaluating mercury exposure level for diagnosis by a provocation test uses chelating agent and conducting to appropriate therapy according to the result. but, indications for the therapy of chelating agents with mercury exposure have not yet been fully established. The therapy to symptomatic patients with mercury poisoning is chelating agents, combination therapy with chelating agents, plasma exchange, hemodialysis, plasmapheresis. But the further evaluations are necessary for the effects and side effects with each therapy.Entities:
Keywords: Diagnosis; Intoxication; Mercury; Treatment
Year: 2016 PMID: 26807265 PMCID: PMC4724159 DOI: 10.1186/s40557-015-0086-8
Source DB: PubMed Journal: Ann Occup Environ Med ISSN: 2052-4374
Overview of chelation drugs for mercury intoxication
| Chemical name (common names, abbreviations) | Dose | Adverse effect | Elements chelated |
|---|---|---|---|
| 2,3-bis(sulfanyl)butanedioic acid (Dimercaptosuccinic acid; DMSA; Succimer) | 10 mg/kg (or 350 mg/m2) q 8 h for 5 days, then 10 mg/kg q 12 h for 14 days (a total of 19 days), P.O. | Gastrointestinal disturbances, mild increase in serum transaminase | Lead, arsenic, mercury, cadmium, silver, tin, copper |
| Sodium 2,3-bis(sulfanyl)propane-1-sulfonate (Sodium (Dimercaptopropanesulfonate; DMPS; Dimaval) | 5 mg/kg q 6–8 h, P.O., I.M.,I.V., SQ | Low back (kidney) pain, gastrointestinal disturbances, skin rash, fatigue, hypersensitivity reactions | Mercury, arsenic, lead, cadmium, tin, silver, copper selenium, zinc, magnesium |
| Children: 5-day courses of 200 or 400 mg of DMPS per m2 surface area per day | |||
| (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid (3-Sulfanyl-D-valine; Penicillamine; D- Penicillamine) | 10 mg/kg/d for 7 days with a possibility of a prolonged treatment during 2 to 3 weeks, P.O. | Interstitial nephritis, hypersensitivity reactions, gastrointestinal disturbances, leukopenia and thrombocytopenia | Copper, arsenic, zinc, mercury, lead |
| 2,3-bis(sulfanyl)propan-1-ol (Dimercaprol; British Anti-Lewisite; BAL) | 50–75 mg/m2 q 4 h for 5 days, deep I.M. | Allergy, gastrointestinal symptoms, tachycardia, fever, elevation of liver function tests | Arsenic, gold, mercury, lead (BAL in combination with) |